JUST HORRIFYING FOOTAGE OF USA FORESTS BEING POISONED AND SUPPRESSED FOR A $13 BILLION ANNUAL BUSINESS .....
PBS NewsHour | Sept. 12, 2012 VIDEO NEWS REPORT
With 30 million acres of forestland, Oregon has a lucrative timber industry that makes $13 billion each year. But some residents are worried about health and environmental risks posed by a common practice to denude all vegation and forest life to increase tree growth by chemical spraying such toxins as Agent Orange 2,4-D.... http://www.pbs.org/newshour/bb/environment/july-dec12/forests_09-12.html
August 14, 2012: Center for Investigative Journalism http://cironline.org/reports/oregonians-fear-harmful-effects-timberland-herbicides-3731
Major USA timber companies – Weyerhaeuser, Roseburg Resources, Stimson Lumber, Seneca Jones and others – have been spraying millions of pounds of herbicide on their "private" forestland in Oregon. But many residents suspect chemicals are being carried on mountain currents, prompting health concerns..... http://cironline.org/reports/oregonians-fear-harmful-effects-timberland-herbicides-3731
SEE: GMO Trees - Eradicating Real Forests to plant Monoculture BioEngineered Trees http://www.scoop.it/t/biodiversity-is-life/p/2568524705/gmo-trees-eradicating-real-forests-to-plant-monoculture-bioengineered-treesAgriculture
What's wrong with tree plantations? http://www.scoop.it/t/biodiversity-is-life/p/2770994964/what-s-wrong-with-tree-plantations
"The Bioeconomy is Bad for Biodiversity", Global Forest Coalition Warns | Climate Connections http://ow.ly/aDX1P
Bio-economy versus biodiversity http://ow.ly/aDXdn
Obama administration issues ‘Bioeconomy Blueprint’ | Climate Connections http://ow.ly/aE7mqMay 5, 2012
"Corporate Monopolies" http://www.etcgroup.org/issues/corporate-monopolies
"The BioEconomy" http://www.etcgroup.org/issues/bioeconomy
This bioeconomy will encompass rural and urban employment while overseeing all health, medicine and agriculture that has any social benefit. Regulatory agencies will be given advantage by having unlimited access to pharmaceutical data to expedite drug production and development.